NO20084048L - Benzimidazoler som har aktivitet ved M1 receptor og deres anvendelser i medisin - Google Patents
Benzimidazoler som har aktivitet ved M1 receptor og deres anvendelser i medisinInfo
- Publication number
- NO20084048L NO20084048L NO20084048A NO20084048A NO20084048L NO 20084048 L NO20084048 L NO 20084048L NO 20084048 A NO20084048 A NO 20084048A NO 20084048 A NO20084048 A NO 20084048A NO 20084048 L NO20084048 L NO 20084048L
- Authority
- NO
- Norway
- Prior art keywords
- benzimidazoles
- receptor
- medicine
- activity
- applications
- Prior art date
Links
- 102000017927 CHRM1 Human genes 0.000 title 1
- 101150073075 Chrm1 gene Proteins 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0605786.3A GB0605786D0 (en) | 2006-03-22 | 2006-03-22 | Compounds |
| PCT/EP2007/052638 WO2007107565A1 (en) | 2006-03-22 | 2007-03-20 | Benzimidazoles which have activity at m1 receptor and their uses in medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20084048L true NO20084048L (no) | 2008-10-20 |
Family
ID=36383995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20084048A NO20084048L (no) | 2006-03-22 | 2008-09-23 | Benzimidazoler som har aktivitet ved M1 receptor og deres anvendelser i medisin |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20100280071A1 (es) |
| EP (1) | EP2004182B1 (es) |
| JP (1) | JP5256187B2 (es) |
| KR (1) | KR20090015027A (es) |
| CN (2) | CN103058990A (es) |
| AR (1) | AR059977A1 (es) |
| AU (1) | AU2007228716A1 (es) |
| BR (1) | BRPI0708999A2 (es) |
| CA (1) | CA2646896A1 (es) |
| CR (1) | CR10314A (es) |
| EA (1) | EA200870360A1 (es) |
| GB (1) | GB0605786D0 (es) |
| IL (1) | IL194206A0 (es) |
| MA (1) | MA30324B1 (es) |
| MX (1) | MX2008012160A (es) |
| NO (1) | NO20084048L (es) |
| NZ (1) | NZ595738A (es) |
| PE (1) | PE20080007A1 (es) |
| SG (1) | SG170752A1 (es) |
| TW (1) | TW200813004A (es) |
| WO (1) | WO2007107565A1 (es) |
| ZA (1) | ZA200807616B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0605785D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| GB0706187D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706167D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706164D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706170D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706174D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| JP2010539218A (ja) | 2007-09-20 | 2010-12-16 | グラクソ グループ リミテッド | Ｍ１受容体にて活性を有する化合物および医薬としてのそれらの使用 |
| JP2010539217A (ja) | 2007-09-20 | 2010-12-16 | グラクソ グループ リミテッド | Ｍ１受容体にて活性を有する化合物および医薬としてのそれらの使用 |
| WO2009124883A1 (en) * | 2008-04-09 | 2009-10-15 | H. Lundbeck A/S | Novel 1,3-dihydro-benzoimidazol-2-ones as m1 agonists |
| GB0817982D0 (en) * | 2008-10-01 | 2008-11-05 | Glaxo Group Ltd | Compounds |
| JP5990980B2 (ja) * | 2012-04-02 | 2016-09-14 | 大日本印刷株式会社 | オランザピンの中間体の製造方法 |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CA3008272A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3393468B1 (en) | 2015-12-22 | 2022-09-14 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| CN107129439A (zh) * | 2016-02-26 | 2017-09-05 | 中国科学院大连化学物理研究所 | 一种化合物、毒蕈碱m受体拮抗剂、组合物及应用 |
| JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 癌を処置する方法 |
| CA3027498A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| EP4117662A4 (en) | 2020-03-10 | 2024-04-03 | X4 Pharmaceuticals, Inc. | METHODS OF TREATING NEUTROPENIA |
| CN113637001A (zh) * | 2021-08-09 | 2021-11-12 | 安康市农业科学研究院 | 一种氟哌利多中间体的合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4040300A1 (de) * | 1990-12-17 | 1992-07-02 | Leifeld Gmbh & Co | Drueckmaschine mit wenigstens einem rollenhalter |
| CA2200468A1 (en) * | 1994-10-27 | 1996-05-09 | Wayne J. Thompson | Muscarine antagonists |
| WO1997016186A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine agonists |
| JPH10330377A (ja) * | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
| IL137149A0 (en) * | 1998-01-19 | 2001-07-24 | Pfizer | 4-(2-keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists |
| ATE302770T1 (de) * | 1999-12-06 | 2005-09-15 | Euro Celtique Sa | Benzimidazolverbindungen die nociceptinrezeptoraffinität haben |
| WO2004089942A2 (en) * | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| WO2003105781A2 (en) * | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| AU2003300902A1 (en) * | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Piperidine derivatives as CCR5 antagonists |
| EP1937670A1 (en) * | 2005-09-30 | 2008-07-02 | Glaxo Group Limited | Benzimidazolones which have activity at m1 receptor |
-
2006
- 2006-03-22 GB GBGB0605786.3A patent/GB0605786D0/en not_active Ceased
-
2007
- 2007-03-20 EA EA200870360A patent/EA200870360A1/ru unknown
- 2007-03-20 NZ NZ595738A patent/NZ595738A/xx not_active IP Right Cessation
- 2007-03-20 TW TW096109422A patent/TW200813004A/zh unknown
- 2007-03-20 AR ARP070101119A patent/AR059977A1/es not_active Application Discontinuation
- 2007-03-20 BR BRPI0708999-6A patent/BRPI0708999A2/pt not_active Application Discontinuation
- 2007-03-20 EP EP07727115.3A patent/EP2004182B1/en active Active
- 2007-03-20 JP JP2009500852A patent/JP5256187B2/ja not_active Expired - Fee Related
- 2007-03-20 WO PCT/EP2007/052638 patent/WO2007107565A1/en not_active Ceased
- 2007-03-20 KR KR1020087025705A patent/KR20090015027A/ko not_active Ceased
- 2007-03-20 CA CA002646896A patent/CA2646896A1/en not_active Abandoned
- 2007-03-20 PE PE2007000306A patent/PE20080007A1/es not_active Application Discontinuation
- 2007-03-20 MX MX2008012160A patent/MX2008012160A/es not_active Application Discontinuation
- 2007-03-20 AU AU2007228716A patent/AU2007228716A1/en not_active Abandoned
- 2007-03-20 CN CN2012102916757A patent/CN103058990A/zh active Pending
- 2007-03-20 US US12/293,625 patent/US20100280071A1/en not_active Abandoned
- 2007-03-20 CN CN2007800188235A patent/CN101448495B/zh not_active Expired - Fee Related
- 2007-03-20 SG SG201102019-5A patent/SG170752A1/en unknown
-
2008
- 2008-09-04 ZA ZA200807616A patent/ZA200807616B/xx unknown
- 2008-09-18 IL IL194206A patent/IL194206A0/en unknown
- 2008-09-23 CR CR10314A patent/CR10314A/es not_active Application Discontinuation
- 2008-09-23 NO NO20084048A patent/NO20084048L/no not_active Application Discontinuation
- 2008-10-07 MA MA31270A patent/MA30324B1/fr unknown
-
2011
- 2011-10-27 US US13/282,610 patent/US20120041028A1/en not_active Abandoned
-
2012
- 2012-08-14 US US13/584,956 patent/US20120316202A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007107565A1 (en) | 2007-09-27 |
| JP5256187B2 (ja) | 2013-08-07 |
| JP2009530347A (ja) | 2009-08-27 |
| IL194206A0 (en) | 2009-08-03 |
| US20120041028A1 (en) | 2012-02-16 |
| CN101448495B (zh) | 2013-05-08 |
| TW200813004A (en) | 2008-03-16 |
| KR20090015027A (ko) | 2009-02-11 |
| US20120316202A1 (en) | 2012-12-13 |
| CR10314A (es) | 2008-12-01 |
| CA2646896A1 (en) | 2007-09-27 |
| SG170752A1 (en) | 2011-05-30 |
| GB0605786D0 (en) | 2006-05-03 |
| MA30324B1 (fr) | 2009-04-01 |
| PE20080007A1 (es) | 2008-03-16 |
| US20100280071A1 (en) | 2010-11-04 |
| EP2004182A1 (en) | 2008-12-24 |
| MX2008012160A (es) | 2008-10-03 |
| EA200870360A1 (ru) | 2009-02-27 |
| AR059977A1 (es) | 2008-05-14 |
| BRPI0708999A2 (pt) | 2011-06-21 |
| AU2007228716A1 (en) | 2007-09-27 |
| NZ595738A (en) | 2012-11-30 |
| EP2004182B1 (en) | 2013-05-08 |
| CN103058990A (zh) | 2013-04-24 |
| CN101448495A (zh) | 2009-06-03 |
| ZA200807616B (en) | 2010-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20084048L (no) | Benzimidazoler som har aktivitet ved M1 receptor og deres anvendelser i medisin | |
| NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
| NO20074275L (no) | 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister | |
| NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
| NO20081844L (no) | Terapeutiske forbindelser | |
| NO20081476L (no) | Substituerte benzimidazoler og fremgangsmater for fremstilling | |
| NO20083717L (no) | Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer | |
| NO20081217L (no) | Nye benzotiazolonderivater | |
| NO20075082L (no) | Pyridin-3-karboksamidderivater som CB1-inversagonister | |
| NO20081729L (no) | Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer | |
| NO20084328L (no) | Nye forbindelser | |
| ATE537168T1 (de) | Substituierte oxazolidinone und ihre verwendung | |
| CY1115789T1 (el) | 2,3-διυδροβενζο[1,4]διοξιν-2-υλομεθυλο παραγωγα ως αλφα2c ανταγωνιστες για χρηση στη θεραπευτικη αγωγη παθησεων του περιφερικου και του κεντρικου νευρικου συστηματος | |
| NO20084307L (no) | Heterocykliske GPCR agonister | |
| NO20075992L (no) | Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav | |
| NO20061454L (no) | Compounds having CRTH2 antagonist activity | |
| EA201170521A1 (ru) | Новые соединения | |
| NO20091247L (no) | terapeutiske pyrazolyl tienopyridiner | |
| NO20071719L (no) | Pyridylinhibitorer for "hedgehog"-signalisering | |
| NO20080061L (no) | Imidazolyl-pyrimidinforbindelser for anvendelse til behandling av proliferative lidelser | |
| NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
| NO20081788L (no) | Cyklopropylaminer som modulatorer av histamin-H3-reseptoren | |
| BRPI0813993A2 (pt) | Ciclopentanos de pirimidila como inibidores de proteína quinase akt | |
| NO20091741L (no) | Pyrazolinforbindelser som mineralkortikoidreceptorantagonister | |
| DK2105164T3 (da) | Nye P2X7R-antagonister og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: GLAXO GROUP LTD, GB |
|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |